System for treating a site where an external fixation device enters the body and a bioelectrical device
A bioelectromedical device using a multi-array matrix of biocompatible microcells generates an electric field to inhibit and kill bacteria at the insertion site of external fixation devices, addressing the challenge of biofilm-related infections and improving treatment outcomes.
Patent Information
- Application Number
- JP2022501068
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-11
- Filing Date
- 2020-01-09
- Publication Date
- 2024-12-05
- Estimated Expiration
- 2040-01-09
AI Technical Summary
External fixation devices used in medical treatments can lead to infections at the site where the connector enters the body, particularly due to biofilm formation by bacteria, which are resistant to antibiotics and difficult to treat.
A bioelectromedical device comprising a multi-array matrix of biocompatible microcells made from dissimilar metals that generate a low-level electric field or microcurrent when in contact with an electrolyte, inhibiting bacterial biofilm formation and killing bacteria through a combination of electric field and antimicrobial agents.
The device effectively prevents and reduces biofilm formation and bacterial growth at the insertion site of external fixation devices, enhancing wound healing and reducing infection risk.
Smart Images

Figure 0007594805000001 
Figure 0007594805000002 
Figure 0007594805000003
Abstract
Description
[Technical field]
[0001] The present disclosure relates to methods and devices useful for maintaining the position of bioelectrical devices used in conjunction with medical devices. [Background technology]
[0002] External fixation is a surgical treatment in which connectors (e.g., rods, pins, or wires) are attached to body structures (e.g., bones) and then exit the body and attached to stabilizing structures outside the body. It is an alternative to internal fixation, where all structures to provide stability are placed inside the patient. External fixation is used to stabilize bone and soft tissues at a location away from the surgical or injury site, providing unobstructed access to the associated bone and soft tissues for initial evaluation and secondary interventions necessary to restore bony continuity and functional soft tissue. However, these fixation devices can result in infection, especially at the site where the connector enters the body (the insertion site). Summary of the Invention [Means for solving the problem]
[0003] Disclosed herein are methods, systems, and devices for treating injuries such as contusions, including bone fractures, the methods, systems, and devices including medical devices, such as bioelectrical therapy devices.
[0004] Also disclosed herein is a bioelectrical medical device comprising a multi-array matrix of biocompatible microcells, the matrix including a first array forming a pattern of microcells formed from a first conductive material including a metallic species, and a second array forming a pattern of microcells formed from a second conductive solution including a metallic species, the metallic species of the second array being capable of defining at least one voltaic cell with the metallic species of the first array for spontaneously generating at least one electrical current when the first and second arrays are introduced into an electrolyte solution and the first and second arrays are not in physical contact with each other.
[0005] The disclosed methods include methods of fixation of a medical device, for example a bioelectric medical device, at a body insertion site of an external fixation device.
[0006] Further aspects include methods of preventing infection, for example inhibiting bacterial biofilm formation. Aspects also include methods of reducing microbial or bacterial growth, killing microbial or bacteria, killing bacteria through a biofilm layer, or inhibiting biofilm formation, or combinations thereof. Embodiments include methods of using the disclosed devices in combination with antibiotics to reduce microbial or bacterial growth, kill microbial or bacteria, kill bacteria through a biofilm layer, or inhibit biofilm formation, or combinations thereof. [Brief description of the drawings]
[0007] [Figure 1] FIG. 2 is a detailed plan view of an embodiment of the present disclosure. [Diagram 2] FIG. 2 is a detailed plan view of an applied pattern of electrically conductive material according to an embodiment of the present disclosure. [Diagram 3] Adhesive bandage using the applied pattern of FIG. 2. [Figure 4] 3. This is a cross-sectional view taken along line 3-3 in FIG. [Diagram 5]FIG. 13 is a detailed plan view of another embodiment disclosed herein, including thin wires of conductive metal solution connected to electrodes. [Figure 6] FIG. 13 is a detailed plan view of another alternative embodiment comprising a line pattern and a dot pattern. [Figure 7] FIG. 13 is a detailed plan view of yet another alternative embodiment with two line patterns. [Figure 8A] 13 illustrates another embodiment showing the location of discontinuous regions similar to anchor regions of a wound management system. [Figure 8B] 13 illustrates another embodiment showing the location of discontinuous regions similar to anchor regions of a wound management system. [Figure 8C] 13 illustrates another embodiment showing the location of discontinuous regions similar to anchor regions of a wound management system. [Figure 8D] 13 illustrates another embodiment showing the location of discontinuous regions similar to anchor regions of a wound management system. [Figure 8E] 13 illustrates another embodiment showing the location of discontinuous regions similar to anchor regions of a wound management system. [Figure 9A] Energy dispersive X-ray spectroscopy (EDS) analysis of an Ag / Zn BED (bioelectric device; referring to embodiments disclosed herein). A. Scanning electron microscope (SEM) image; B. Optical microscope image; C and DB, close-ups of gold and gray dots, respectively; E. EDS elemental map of zinc; F. EDS elemental map of silver; G. EDS elemental map of oxygen; H. EDS elemental map of carbon. Scale bars are 1 mm for B, E-H, and 250 μm for C, D. [Figure 9B] Spectrophotometric and CFU determinations of planktonic PAO1 cultures treated with placebo, Ag / Zn BED, and placebo + Ag dressings. [Figure 9C] Spectrophotometric and CFU determinations of planktonic PAO1 cultures treated with placebo, Ag / Zn BED, and placebo + Ag dressings. [Figure 9D] Zone of inhibition for placebo, Ag / Zn BED, and placebo + Ag dressing. [Figure 10]1 shows scanning electron microscopy images of in vitro PAO1 biofilms treated with placebo, an embodiment disclosed herein ("BED"), and placebo+Ag dressings. [Figure 11] EPS staining is shown. [Figure 12] Live / Dead staining is shown, with green fluorescence indicating live PAO1 bacteria and red fluorescence indicating dead bacteria. [Figure 13A] PAO1 staining is shown. [Figure 13B] PAO1 staining is shown. [Figure 13C] PAO1 staining is shown. [Figure 14] 1 shows real-time PCR for evaluating the expression of quorum sensing genes. [Figure 15A] 1 shows EPR spectra using DEPMPO, spin adduct formation upon exposure to disclosed embodiments in PBS for 40 minutes. [Figure 15B] 1 shows EPR spectra using DEPMPO, spin adduct formation upon exposure to disclosed embodiments in PBS for 40 minutes. [Figure 16] Real-time PCR performed to assess mex gene expression upon treatment with Ag / Zn BED and 10 mM DTT is shown. [Figure 17A] The enzyme activity of glycerol-3-phosphate dehydrogenase is shown. OD was measured in kinetic mode. [Figure 17B] The enzyme activity of glycerol-3-phosphate dehydrogenase is shown. GPDH activity was calculated as glycerol-3-phosphate dehydrogenase activity = B / (ΔT × V) × dilution factor = nmol / min / ml. B = amount of NADH from the standard curve (nmol), ΔT = reaction time (min), V = amount of sample added to reaction well (ml). [Figure 18] 1 shows a dressing clip as is described herein. [Figure 19] 1 shows a rear view of the disclosed device. [Figure 20] 1 shows a front view of the disclosed device. [Figure 21] 1 shows the disclosed device when used in conjunction with a fixation rod from an external fixation device. [Figure 22] FIG. 2 is a bottom view of the disclosed device showing the slits and rod passage holes. [Diagram 23] Shows the external fixation device in use DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] The embodiments disclosed herein include a system for preventing infection associated with an external fixation device. The system may include a bioelectrical medical device, such as a dressing, and a fixation device. The fixation device may include a "pin-clip" fixation device (see FIG. 18). The clip may include a "slit" or "groove" 180 with a circular area 185 that may accommodate a connector or pass-through (e.g., a fixation rod or wire) of the external fixation device. In an embodiment, the slit or groove may extend from the periphery of the device 187 toward the center of the device, for example, to allow the clip to slide over a fixation rod. FIG. 19 shows a rear view of a disclosed embodiment with a high "bump" 190 to aid in fixation and removal of the device.
[0009] In embodiments, the clip is constructed from a medically acceptable material, such as metal, plastic, etc. In embodiments, the clip can be sterilized, for example, using radiation or an autoclave.
[0010] The bioelectric dressing is capable of applying a low level electric field (LLEF) to a tissue or organism (hence an "LLEF system"), or, when in contact with a conductive material, a low level microcurrent (LLMC) to a tissue or organism (hence an "LLMC system"). Thus, in an embodiment, the LLMC system is an LLEF system in contact with a conductive material. In an embodiment, the microcurrent or electric field is adjustable, for example, to vary the duration, size, shape, field depth, current, polarity, or voltage of the system. The device can also generate a localized electric field in a pattern determined by the distance between the cells or electrodes, and the physical direction and / or magnitude. The effective depth of the electric field can be predetermined by the direction and distance between the cells or electrodes, and the physical direction and / or magnitude. In an embodiment, the device can be fully or partially coated with hydrogel or glucose, a drug, a cell nutrient composition, stem cells, or other biological material. In an embodiment, the electric field can be extended, for example, through the use of a hydrogel. In some embodiments, such as in a method of treatment, it may be preferable to utilize an AC or DC power source. In embodiments that use an AC power source, certain aspects of the power source may be adjusted, for example, the frequency, amplitude, phase, waveform shape, period, and pulse duration.
[0011] The embodiments disclosed herein comprise biocompatible electrodes, or reservoirs, or dots on a surface, such as, for example, a fabric. In an embodiment, the surface is flexible. In an embodiment, the surface comprises gauze or mesh. Suitable types of flexible surfaces for use in the embodiments of the present disclosure are cloth, absorbent textiles, low-adhesion, vapor-permeable films, hydrocolloids, hydrogels, alginates, foams, foam-like materials, cellulosic materials including Kettenbach fibers, hollow tubes, fibrous materials such as those saturated with anhydrous / hygroscopic materials, beads, etc., or any suitable material known in the art. In an embodiment, the flexible material can form, for example, a bandage, dressing, etc. The embodiments can include coating the surface, such as, for example, on or between the electrodes. Such coatings can include, for example, mixtures of silicone and electrolytes, hypoallergenic agents, drugs, biological materials, stem cells, skin substitutes, blood clotting agents, or anticoagulants, etc. Medications suitable for use in the embodiments as described herein include painkillers, antibiotics, anti-inflammatories, etc. In embodiments, the generated electric field or current can "drive" the medication through the skin or tissue surface.
[0012] The LLMC or LLEF system disclosed herein may comprise a reinforcement section. In embodiments, the reinforcement section may comprise a portion that spans the length of the system. In embodiments, the LLMC or LLEF system may comprise a plurality of reinforcements, such as at least one reinforcement section, at least two reinforcements, at least three reinforcements, at least four reinforcements, at least five reinforcements, at least six reinforcements, etc.
[0013] In embodiments, the LLMC or LLEF system may include additional materials such as activating gel, rhPDGF (recombinant human platelet derived growth factor) (REGRANEX®), vibronectin:IGF complex, CELLSPRAY (Clinical Cell Culture, Australia), RECELL® (Clinical Cell Culture, Australia), INTEGRA® Dermal Regeneration Template (Integra Life Sciences, USA), BIOMEND® (Zimmer Dental, USA), INFUSE® (Medtronic Sofamor Danek, USA), ALLODERM® (LifeCell, USA), CYMETRA® (LifeCell, USA), SEPRAPACK® (Genzyme, USA), SEPRAMESH® (Genzyme, USA), SKINTEMP® (Human BioSciences, USA), COSMODERM® (Inamed, USA), COSMOPLAST® (Inamed, USA), OP-1® (Stryker, USA), ISOLAGEN® (Fibrocell Technologies, USA), CARTICEL® (Genzyme, USA), APLIGRAF® (Sandoz AG, Switzerland), DERMAGRAFT® (Smith & Nephew Wound Management, USA), TRANSCYTE® (Shire Regenerative Medicine, USA), ORCEL® (Orcell LLPC, USA), EPICEL® (Genzyme, USA), and the like.In embodiments, the additional material may be, for example, TEGADERM® 91110 (3M, USA), MEPILEX® Normal Gel 0.9% Sodium Chloride (Molnlycke Health Care AB, Sweden), HISPAGEL® (BASF, USA), LUBRIGEL® (Sheffield Laboratories, USA), or other compositions useful for maintaining a moist environment for the body or for facilitating removal of the LLMC or LLEF system. In certain embodiments, additional materials that may be added to the LLMC or LLEF system may include, for example, a vesicle-based formulation, such as hemoglobin vesicles. In certain embodiments, a liposome-based formulation may be used. An embodiment may include an antimicrobial material, such as a gel or liquid.
[0014] In an embodiment, the LLMC or LLEF system may include instructions or instructions on how to deploy the system to maximize performance.
[0015] As used herein, "activating gel" means a composition useful for maintaining a moist environment in the area to be treated or for increasing the electrical conductivity of the area to be treated.
[0016] As used herein, "affixing" means contacting a device or system of the present disclosure to a patient or tissue.
[0017] As used herein, "applied" or "applying" refers to contacting a conductive material to a surface, such as by printing, painting, or spraying a conductive ink onto the surface. Alternatively, "applying" can refer to contacting a patient or tissue or organism with a device or system of the present disclosure.
[0018] A "BED" or "Bioelectric Device" is a LLMC or LLEF system as disclosed herein.
[0019] A "biofilm" is any group of microorganisms in which cells are attached to each other, for example, on a surface. These attached cells are often embedded in a matrix of self-assembled extracellular polymeric substances (EPS). Biofilm extracellular polymeric substances (also called "slime") are generally polymeric assemblies composed of extracellular DNA, proteins, and polysaccharides. Biofilms can form on living or non-living surfaces and can be widespread in natural, industrial, and hospital environments. Microbial cells growing in biofilms are physiologically different from planktonic cells of the same organisms, which in contrast are single cells that can float or swim in liquid media. A variety of bacteria form biofilms, including gram-positive bacteria (e.g., Bacillus spp, Listeria monocytogenes, Staphylococcus spp, and lactic acid bacteria, including Lactobacillus plantarum and Lactococcus lactis), gram-negative bacteria (e.g., Escherichia coli or Pseudomonas aeruginosa).
[0020] As used herein, "conductive material" refers to an object or type of material that allows the flow of an electric charge in one or more directions. Conductive materials can include solids, such as metals or carbon, or liquids, such as conductive metal solutions and conductive gels. Conductive materials can be applied to form at least one matrix. Conductive liquids can be allowed to dry, harden or solidify after application to form a solid material.
[0021] As used herein, "connector" refers to a mechanical connection into or out of the body that connects the interior of the fixation device with the exterior.
[0022] As used herein, "discontinuous regions" refers to "voids" in a material, such as holes, slots, etc. Typically, voids have a fixed shape, but the term can refer to any void in a material. A void in a material can be entirely within the perimeter of the material or can extend to the peripheral regions of the material.
[0023] As used herein, a "dot" refers to an individual deposit of different reservoirs that functions as at least one battery cell. The term can refer to a deposit of any suitable size or shape, such as a square, circle, triangle, line, etc. The term can be used synonymously with microcell, etc.
[0024] "Electrodes" refer to homogeneous or heterogeneous conductive materials. In embodiments using an external power source, the electrodes comprise homogeneous conductive materials. In embodiments not using an external power source, the electrodes comprise heterogeneous conductive materials that can define an anode and a cathode.
[0025] As used herein, "expandable" refers to the ability to maintain structural integrity and stretch without rupturing. The term refers to solid regions as well as discontinuous or "void" regions, and the solid regions as well as the void regions may stretch or expand.
[0026] "External fixation connector" refers to the mechanical attachment between the frame of the external fixation device and the patient. For example, the external fixation connector can be a rod, wire, etc.
[0027] As used herein, "matrix" refers to the pattern formed by electrodes on a surface. The matrix can be designed to vary the electric field or electric microcurrent that is generated. For example, the strength and shape of the electric field or microcurrent can be varied, or the matrix can be designed to generate an electric field or current of a desired strength or shape.
[0028] As used herein, "stretchable" refers to the ability of an embodiment to stretch without losing structural integrity, i.e., the embodiment can stretch to accommodate an irregular wound surface or a surface where portions of the surface may move relative to other portions of the surface.
[0029] As used herein, a "wound" includes connector insertion sites, abrasions, surgical wounds, cuts, puncture wounds, lacerations, sores, ulcers, blisters, burns, cuts, bites, and any other hole, tear or break in superficial tissue such as skin, mucous membranes, epithelial layers, and the like. Breaks may include sites of inflammation, polyps, ulcers, and the like. Scars are intended to include either hypertrophic scars, keloids, or healed wound tissue in other diseased individuals. Superficial tissue includes tissue that is not normally exposed in the absence of a wound or tear, such as underlying muscle or connective tissue. Wounds need not be visible or involve laceration of superficial tissue, for example, wounds may contain bacterial infections. Wounds may include insect and animal bites, both by venomous and non-venomous insects and animals.
[0030] LLMC / LLEF system, manufacturing method
[0031] An embodiment of the LLMC or LLEF system disclosed herein can include electrodes or microcells. Each electrode or microcell can be or include a conductive metal. In embodiments, the electrodes or microcells can include any conductive material, for example, electrically conductive hydrogels, metals, electrolytes, superconductors, semiconductors, plasmas, and non-metallic conductive materials such as graphite and conductive polymers. Electrically conductive metals can include silver, copper, gold, aluminum, molybdenum, zinc, lithium, tungsten, brass, carbon, nickel, iron, palladium, platinum, tin, bronze, carbon steel, lead, titanium, stainless steel, mercury, Fe / Cr alloys, and the like. The electrodes can be coated or plated with different metals, such as aluminum, gold, platinum, or silver.
[0032] In certain embodiments, the geometry of the reservoirs or electrodes or cells can comprise circles, polygons, lines, zigzags, ellipses, stars, or any suitable variety of shapes, providing the ability to design / customize the surface electric field shape as well as the depth of penetration.
[0033] The size and concentration of the reservoirs or dots can be of various sizes, as variations allow for changes in the characteristics of the electric field generated. One embodiment provides an electric field of about 1 volt, which produces a current in the range of 10 μA under normal tissue with a resistance of 100k to 300k ohms. The strength of the electric field can be determined by calculating 1 / 2 the separation distance and applying it to the z-axis on the midpoint between the cells. This indicates the theoretical location of the strongest field lines.
[0034] In some embodiments, dissimilar metals can be used to create an electric field of a desired voltage, hi some embodiments, the pattern of reservoirs can control the watt density and shape of the electric field.
[0035] In embodiments, "ink" or "paint" can comprise any conductive solution suitable for forming electrodes on a surface, such as a conductive metal solution. In embodiments, "printing" or "applying" includes any method of applying a conductive material, such as a conductive liquid material, to a material on which a matrix is desired.
[0036] In embodiments, a printing device can be used to manufacture the LLMC or LLEF systems of the present disclosure. For example, an inkjet or "3D" printer can be used to manufacture the embodiments.
[0037] In an embodiment, the binder or ink used to manufacture the LLMC or LLEF system of the present disclosure can include, for example, polycellulose ink, polyacrylic ink, polyurethane ink, polysilicone ink, etc. In an embodiment, the type of ink used can determine the release rate of electrons from the reservoir. In an embodiment, various materials can be added to the ink or binder, for example, conductive or resistive materials can be added to change the shape or strength of the electric field. Other materials, such as silicone, can be added to enhance scar reduction. Such materials can also be added to the spaces between the reservoirs.
[0038] The power source can be any energy source capable of producing an electrical current in the LLMC system and can include, for example, an AC power source, a DC power source, radio frequency (RF) such as pulsed RF, induction, ultrasound, etc. Some embodiments can use a power source such as a battery or microbattery to generate the electrical current.
[0039] The dissimilar metals used to make the LLMC or LLEF systems of the present disclosure can be, for example, silver and zinc, and the electrolyte can include sodium chloride in water. In an embodiment, the electrodes are applied onto a non-conductive surface to generate a pattern, most preferably an array or multi-array of voltaic cells that do not react spontaneously until the electrodes come into contact with an electrolyte, such as wound fluid, including physiological fluids such as blood, sweat, lymphatic fluid, etc. This description section uses the term "printing" with "ink," but it is understood that the pattern may instead be "printed" using a "paint." The use of any suitable method for applying the conductive material is contemplated. In embodiments, the "ink" or "paint" can comprise any solution suitable for forming electrodes on a surface, such as a conductive material including a conductive metal solution. In embodiments, "printing" or "printed" can comprise any method of applying a solution to a material on which a matrix is desired. It is also assumed that a competent practitioner would know how to properly apply and cure the solution without any assistance, perhaps even instructions that should be included with the selected binder used to create the mixture used in the printing process.
[0040] A preferred material to combine with silver to create the voltaic cell or reservoir of the disclosed embodiments is zinc. Zinc has well-described uses in topical antibacterial agents such as bacitracin zinc, the zinc salt of bacitracin, to prevent infection. Zinc is a divalent cation that has its own antibacterial properties in addition to having the added benefit of being a cofactor for proteins in the metalloproteinase family of enzymes that are important for the phagocyte debridement and remodeling stages of wound healing. The zinc cofactor promotes and accelerates the functional activity of these enzymes, resulting in better and more effective wound healing.
[0041] 1, dissimilar electrodes, a first electrode 6 and a second electrode 10, are provided on a desired major surface 2 of an article 4. In one embodiment, the major surface is the surface of the LLMC or LLEF system that will be in direct contact with the area to be treated, such as a skin surface or wound, for example, at the insertion point. In another embodiment, the major surface 2 is one that is desired to be antimicrobial, such as a medical device, implant, surgical gown, glove, sock, table, doorknob, or other surface that will come into contact with electrolyte, including sweat, and at least a portion of the voltaic cell pattern will spontaneously react to kill bacteria or other microorganisms.
[0042] In various embodiments, the difference in standard potential between the electrodes, or dots, or reservoirs can range from 0.05 V to about 5.0 V. For example, the standard potentials can be 0.05 V, 0.06 V, 0.07 V, 0.08 V, 0.09 V, 0.1 V, 0.2 V, 0.3 V, 0.4 V, 0.5 V, 0.6 V, 0.7 V, 0.8 V, 0.9 V, 1.0 V, 1.1 V, 1.2 V, 1.3 V, 1.4 V, 1.5 V, 1.6 V, 1.7 V, 1.8 V, 1.9 V, 2.0 V, 2.1 V, 2.2 V, 2.3 V, 2.4 V, 2.5 V, 2.6 V, 2.7 V, 2.8 V, 2.9 V, 3.0 V, 3.1 V, 3.2 V, 3.3 V, 3.4 V, 3.5 V, 3.6 V, 3.7 V, 3.8 V, 3.9 V, 4.0 V, 4.1 V, 4.2 V, 4.3 V, 4.4 V, 4.5 V, 4.6 V, 4.7 V, 4.8 V, 4.9 V, 5.0 V, 5.1 V, 5.2 V, 5.3 V, 5.4 V, 5.5 V, 5.6 V, 5.7 V, 5.8 V, 5.9 V, 6.0 V, 6.1 V, 6.2 V, 6.3 V, 6.4 V, 6.5 V, 6.6 V, 6.7 V, 6.8 V, 6.9 V, 7.0 V, 7.1 V, 7. 7V, 2.8V, 2.9V, 3.0V, 3.1V, 3.2V, 3.3V, 3.4V, 3.5V, 3.6V, 3.7V, 3.8V, 3.9V, 4.0V, 4.1V, 4.2V, 4.3V, 4.4V , 4.5V, 4.6V, 4.7V, 4.8V, 4.9V, 5.0V, 5.1V, 5.2V, 5.3V, 5.4V, 5.5V, 5.6V, 5.7V, 5.8V, 5.9V, 6.0V etc.
[0043] In certain embodiments, the difference in standard potential between the electrodes or dots or reservoirs is at least 0.05V, at least 0.06V, at least 0.07V, at least 0.08V, at least 0.09V, at least 0.1V, at least 0.2V, at least 0.3V, at least 0.4V, at least 0.5V, at least 0.6V, at least 0.7V, at least 0.8V, at least 0.9V, at least 1.0V, at least 1.1V, at least 1.2V, at least 1.3V, at least 1.4V, at least 1.5V, at least 1.6V, at least 1.7V, at least 1.8V, at least 1.9V, at least 2.0V, at least 2.1V, at least 2.2V, at least 2.3V, at least 2.4V, at least 2.5V, at least 2.6V, at least 2.7V, at least 2.8V, at least 2.9V, at least 3.0V, at least 3.1V, at least 3.2V, at least 3.3V, at least 3.4V, at least 3.5V, at least 3.6V, at least 3.7V, at least 3.8V, at least 3.9V, at least 4.0V, at least 4.0V, at least 4.1V, at least 4.2V, at least 4.3V, at least 4.4V, at least 4.5V, at least 4.6V, at least 4.7V, at least 4.8V, at least 4.9V, at least 5.0V, at least 5.1V, at least 5.2V, at least 5.3V, at least 5.4V, at least 5.5 It can be at least 6V, at least 2.7V, at least 2.8V, at least 2.9V, at least 3.0V, at least 3.1V, at least 3.2V, at least 3.3V, at least 3.4V, at least 3.5V, at least 3.6V, at least 3.7V, at least 3.8V, at least 3.9V, at least 4.0V, at least 4.1V, at least 4.2V, at least 4.3V, at least 4.4V, at least 4.5V, at least 4.6V, at least 4.7V, at least 4.8V, at least 4.9V, at least 5.0V, at least 5.1V, at least 5.2V, at least 5.3V, at least 5.4V, at least 5.5V, at least 5.6V, at least 5.7V, at least 5.8V, at least 5.9V, at least 6.0V, etc.
[0044] In certain embodiments, the difference in standard potential between the electrodes or dots or reservoirs is 0.05V or less, 0.06V or less, 0.07V or less, 0.08V or less, 0.09V or less, 0.1V or less, 0.2V or less, 0.3V or less, 0.4V or less, 0.5V or less, 0.6V or less, 0.7V or less, 0.8V or less, 0.9V or less, 1.0V or less, 1.1V or less, 1.2V or less, 1.3V or less, 1.4V or less, 1.5V or less, 1.6V or less, 1.7V or less, 1.8V or less, 1.9V or less, 2.0V or less, 2.1V or less, 2.2V or less, 2.3V or less, 2.4V or less, 2.5V or less, 2.6V or less, 2.7V or less, 2.8V or less, 2.9V or less, 3.0V or less, 3.1V or less, 3.2V or less, 3.3V or less, 3.4V or less, 3.5V or less, 3.6V or less, 3.7V or less, 3.8V or less, 3.9V or less, 4.0V or less, 4.1V or less, 4.2V or less, 4.3V or less, It can be 4.4V or less, 4.5V or less, 4.6V or less, 4.7V or less, 4.8V or less, 4.9V or less, 5.0V or less, 5.1V or less, 5.2V or less, 5.3V or less, 5.4V or less, 5.5V or less, 5.6V or less, 5.7V or less, 5.8V or less, 5.9V or less, 6.0V or less, etc.
[0045] In embodiments, the LLMC system can generate low level microcurrents, for example, between about 1 and about 200 microamps, between about 10 and about 190 microamps, between about 20 and about 180 microamps, between about 30 and about 170 microamps, between about 40 and about 160 microamps, between about 50 and about 150 microamps, between about 60 and about 140 microamps, between about 70 and about 130 microamps, between about 80 and about 120 microamps, between about 90 and about 100 microamps, etc.
[0046] In embodiments, the LLMC system can generate low level microcurrents, for example, between about 1 and about 400 microamps, between about 20 and about 380 microamps, between about 400 and about 360 microamps, between about 60 and about 340 microamps, between about 80 and about 320 microamps, between about 100 and about 3000 microamps, between about 120 and about 280 microamps, between about 140 and about 260 microamps, between about 160 and about 240 microamps, between about 180 and about 220 microamps, etc.
[0047] In embodiments, the LLMC system may be configured to provide a current of about 10 microamps, about 20 microamps, about 30 microamps, about 40 microamps, about 50 microamps, about 60 microamps, about 70 microamps, about 80 microamps, about 90 microamps, about 100 microamps, about 110 microamps, about 120 microamps, about 130 microamps, about 140 microamps, about 150 microamps, about 160 microamps, or a combination of the above. , about 170 microamps, about 180 microamps, about 190 microamps, about 200 microamps, about 210 microamps, about 220 microamps, about 240 microamps, about 260 microamps, about 280 microamps, about 300 microamps, about 320 microamps, about 340 microamps, about 360 microamps, about 380 microamps, about 400 microamps, and the like.
[0048] In embodiments, the LLMC system provides a current limiting current (I / O) of 10 microamps or less, or 20 microamps or less, 30 microamps or less, 40 microamps or less, 50 microamps or less, 60 microamps or less, 70 microamps or less, 80 microamps or less, 90 microamps or less, 100 microamps or less, 110 microamps or less, 120 microamps or less, 130 microamps or less, 140 microamps or less, 150 microamps or less, 160 microamps or less, 170 microamps or less, 180 microamps or less, 190 microamps or less, 200 microamps or less, 210 microamps or less, 220 microamps or less, 230 microamps or less, 240 microamps or less, 250 microamps or less, 260 microamps or less, 270 microamps or less, 280 microamps or less, 290 microamps or less, 300 microamps or less, 310 microamps or less, 320 microamps or less, 330 microamps or less, 340 microamps or less, 350 microamps or less, 360 microamps or less, 370 microamps or less, 380 microamps or less, 390 microamps or less, 400 microamps or less, 410 microamps or less, 420 microamps or less, 430 microamps or less, 440 microamps or less, 450 microamps or less, 460 microamps or less, 470 microamps or less, 480 microamps or less, 490 microamps or less, 500 microamps or less It can generate low level microcurrents such as below 100µA, below 220µA, below 230µA, below 240µA, below 250µA, below 260µA, below 270µA, below 280µA, below 290µA, below 300µA, below 310µA, below 320µA, below 340µA, below 360µA, below 380µA, below 400µA, below 420µA, below 440µA, below 460µA, below 480µA, etc.
[0049] In embodiments, the LLMC system may be configured to provide a current limiting function for a LLMC system that is 10 microamps or more, 20 microamps or more, 30 microamps or more, 40 microamps or more, 50 microamps or more, 60 microamps or more, 70 microamps or more, 80 microamps or more, 90 microamps or more, 100 microamps or more, 110 microamps or more, 120 microamps or more, 130 microamps or more, 140 microamps or more, 150 microamps or more, 160 microamps or more, 170 microamps or more, 180 microamps or more, 190 microamps or more, 200 microamps or more, 210 microamps or more, 220 microamps or more, 230 microamps or more, 240 microamps or more, 250 microamps or more, 260 microamps or more, 270 microamps or more, 280 microamps or more, 290 microamps or more, 300 microamps or more, 310 microamps or more, 320 microamps or more, 330 microamps or more, 340 microamps or more, 350 microamps or more, 360 microamps or more, 370 microamps or more, 380 microamps or more, 390 microamps or more, 400 microamps or more, 410 microamps or more, 420 microamps or more, 430 microamps or more, 440 microamps or more, 450 microamps or more, 460 microamps or more, 470 microamps or more, 480 microamps or more, 490 microamps or more, 500 It can generate low level microcurrents such as 10 ...
[0050] The biocompatible binder is mixed in an embodiment into a separate mixture with each of the dissimilar metals creating the pattern of the voltaic cell in the embodiment, so that the applied electrodes or reservoirs or dots can be adhered or bonded to the desired major surface 2. Most inks are simply carriers, with the binder mixed with the pigment. Similarly, the conductive metal solution can be a binder mixed with the conductive elements. The resulting conductive metal solution can be used with application methods such as screen printing to apply the electrodes to the major surface in a predetermined pattern. Once the conductive metal solution dries and / or hardens, the pattern of spaced apart electrodes can substantially maintain their respective positions, even on flexible materials such as those used in LLMC or LLEF systems. To create the limited number of embodiments of the system disclosed herein, the conductive metal solution can be applied manually onto a common adhesive dressing, resulting in an array of alternating electrodes spaced approximately one millimeter apart on the major surface of the dressing. The solution must be dried before being applied to the surface to avoid mixing of the conductive materials that would destroy the array and cause a direct reaction that would open the elements but fail to simulate the current of injury. However, even if the materials are mixed, the wound management system still exhibits antimicrobial efficacy. Furthermore, while only silver has demonstrated antimicrobial efficacy, embodiments exhibit superior antimicrobial activity to silver alone.
[0051] In certain embodiments using polycellulose binders, the binder itself may have beneficial effects such as reducing the local concentration of matrix metalloproteinases through the process of iontophoresis to deliver cellulose into the surrounding tissue or by the presence of an electric field, which can be used to electrically deliver other components such as drugs to the surrounding tissue.
[0052] The binder may include any biocompatible liquid material that can be mixed with conductive elements (preferably silver or zinc metallic crystals) to create a conductive solution that can be applied as a thin coating to a surface. Other suitable binders are solvent-dilutable polymers, such as polyacrylic non-toxic silk screen inks manufactured by COLORCONR®, a division of Berwind Pharmaceutical Services (COLORCONR® NO-TOXR® product line, see part number NT28). In an embodiment, the binder is mixed with high purity (at least 99.99%) metallic silver crystals to create a silver conductive solution. In further embodiments, the purity of the crystals may be less, for example 99%, or 97%, or 96%, or 95%, or 93%, or 90%, or 88%, or less.
[0053] The silver crystals, which may be produced by crushing silver into powder, are preferably less than 100 microns in size, or nearly as fine as powder. In an embodiment, the size of the crystals is generally about 40 microns in size or slightly smaller, about 325 mesh. The binder is mixed separately with high purity (in an embodiment, at least 99.99%) metallic zinc powder, preferably sieved through a standard 325 mesh screen, to produce the zinc conductive solution. For better quality control and more consistent results, the majority of the crystals used should be larger than 325 mesh and smaller than 200 mesh. For example, the crystals used should be between 200 mesh and 325 mesh, or between 210 mesh and 310 mesh, between 220 mesh and 300 mesh, between 230 mesh and 290 mesh, between 240 mesh and 280 mesh, between 250 mesh and 270 mesh, between 255 mesh and 265 mesh, etc.
[0054] Other powders of metals can be used to make other conductive metal solutions in the same manner as described in the other embodiments.
[0055] The size of the metal crystals, the surface availability to the conductive liquid, and the ratio of metal to binder can affect the release rate of the metal from the mixture. When using COLORCON® polyacrylic ink as the binder, for longer-term dressings (e.g., those that are left in place for about 10 days), about 10 to 40 percent of the mixture should be metal. For example, for longer-term LLMC or LLEF systems, the percentage of the mixture that should be metal can be 8 percent, or 10 percent, 12 percent, 14 percent, 16 percent, 18 percent, 20 percent, 22 percent, 24 percent, 26 percent, 28 percent, 30 percent, 32 percent, 34 percent, 36 percent, 38 percent, 40 percent, 42 percent, 44 percent, 46 percent, 48 percent, 50 percent, etc. In an embodiment, a polycellulose ink can be used as the binder.
[0056] If the same binder is used, but the percentage of metal in the mixture is increased to 60 percent or more, the release rate becomes faster and typical systems are effective for only a few days. For example, for a shorter term dressing, the percentage of the mixture to be metal can be 40 percent, or 42 percent, 44 percent, 46 percent, 48 percent, 50 percent, 52 percent, 54 percent, 56 percent, 58 percent, 60 percent, 62 percent, 64 percent, 66 percent, 68 percent, 70 percent, 72 percent, 74 percent, 76 percent, 78 percent, 80 percent, 82 percent, 84 percent, 86 percent, 88 percent, 90 percent, etc.
[0057] It should be noted that polyacrylic inks can crack if applied as very thin coatings so that the spontaneously reacting metal crystals become more exposed. For LLMC or LLEF systems that include clothing, it is desirable to reduce the percentage of metal to 5 percent or less, or to use a binder that allows the crystals to be embedded more deeply, so that the major surfaces have antimicrobial properties for a very long period of time and do not wear off too quickly. Other binders will dissolve or otherwise degrade faster or slower than polyacrylic inks, and adjustments can be made to obtain the desired rate of spontaneous reaction from the voltaic cell.
[0058] To maximize the number of voltaic cells, in various embodiments, silver chunks or electrodes or reservoirs and zinc chunks or electrodes or reservoirs can instead generate an array of current across the major surface. A basic pattern, as shown in FIG. 1, has each chunk of silver equally spaced from the four chunks of zinc, with each chunk of zinc equally spaced from the four chunks of silver, according to an embodiment. A first electrode 6 is separated from a second electrode 10 by a spacing 8. The design of the first electrode 6 and the second electrode 10 is simply a round dot, which is repeated in an embodiment. Multiple iterations 12 of the design result in a pattern. For a wound management system or dressing, in an embodiment, each silver design is a chunk about twice the size of each zinc design. For the pattern of FIG. 1, the silver design is most preferably about one millimeter from the nearest four zinc designs, and vice versa. The resulting pattern of dissimilar metal chunks defines an array of voltaic cells when introduced into an electrolyte. Further disclosure regarding methods for manufacturing microarrays can be found in U.S. Patent Publication No. 7,813,806, entitled CURRENT PRODUCING SURFACE FOR TREATING BIOLOGIC TISSUE, issued October 12, 2010, which is incorporated by reference in its entirety.
[0059] A cluster of dot patterns, such as the alternating round dots of FIG. 1, is preferred when applying conductive materials to flexible materials, such as those used for wound dressings, because the dots do not significantly affect the flexibility of the material. For general use, the pattern of FIG. 1 is preferred. To maximize the current density on the major surface, the pattern 14 of FIG. 2 can be used. The first electrode 6 of FIG. 2 is a large hexagonal dot, and the second electrode 10 is a pair of smaller hexagonal dots spaced apart from each other. The spacing 8 between the first electrode 6 and the second electrode 10 maintains a relatively consistent distance between the adjacent sides of these designs. Multiple repetitions 12 of the design result in a pattern 14 that may be represented by at least one of the first design surrounded by six of the hexagonal dots of the second design. The pattern 14 of FIG. 2 is well suited for abrasions and burns as well as insect bites, including those in which bacteria or microorganisms or other organisms are carried from the insect. Of course, other patterns may be printed that provide similar effects.
[0060] Figures 3 and 4 show how the pattern of Figure 2 can be used to make an adhesive bandage. The pattern shown in detail in Figure 2 is provided on a major surface 2 of a wound dressing material. The back surface 20 of the printed dressing material is secured to an absorbent wound dressing layer 22, such as cotton. The absorbent dressing layer is adhesively secured to the stretchable adhesive layer 16 such that there is at least one overlapping portion or anchor 18 of the stretchable adhesive layer that can be used to secure a wound management system over the wound.
[0061] FIG. 5 shows additional features that can be added during the design to initiate current flow in a weak electrolyte. A wire 24 is printed along the current path of each voltaic cell with one of the conductive metal solutions. The wire reacts directly at first, but is depleted as the distance between the electrodes increases where maximum voltage is realized. The initial current generated is intended to help control edema so that the LLMC system can be effective. If the electrolyte is highly conductive, the wire will be depleted quickly when the system is first applied and the dressing will function as if the wire was not present.
[0062] Figures 6 and 7 show alternative patterns using at least one line design. The first electrode 6 in Figure 6 is a circular dot similar to the first design used in Figure 1. The second electrode 10 in Figure 6 is a line. When the designs are repeated, they define a pattern of parallel lines separated by a number of spaced apart dots. Figure 7 uses only a line design. The pattern in Figure 7 is well suited for cuts, especially if the lines are perpendicular to the wound. The first electrode 6 can be thicker or wider than the second electrode 10 if the redox reaction requires more metal from the first conductive element (mixed into the conductive metal solution of the first design) compared to the second conductive element (mixed into the conductive metal solution of the second design). The lines can be dashed. Another pattern can be a silver grid line with a zinc lump in the center of each cell of the grid. The pattern can be letters printed from an alternative conductive material so that a message, perhaps identifying a brand name, or information such as the patient's blood type, can be printed on the major surface.
[0063] The spontaneous redox reaction of silver and zinc used a ratio of approximately 2 parts silver to 1 part zinc, so in an embodiment, the silver design can include a mass about twice as large as the zinc design. With a gap of about 1 mm between the closest dissimilar metals (closest edge to closest edge), each voltaic cell in the wound fluid can produce a potential of about 1 volt that will substantially penetrate through the dermis and neodermis. Closer spacing of the dots reduces resistance, provides a lower potential, and the current will not penetrate as deeply. When the spacing is less than about 1 / 10 of a millimeter, the advantages of the spontaneous reaction, which is also present in the direct reaction, are that the silver is electrically transported to the wound, but the wound currents may not be substantially simulated. Therefore, the spacing between the most adjacent conductive materials is 0.1mm, 0.2mm, 0.3mm, 0.4mm, 0.5mm, 0.6mm, 0.7mm, 0.8mm, 0.9mm, 1mm, 1.1mm, 1.2mm, 1.3mm, 1.4mm, 1.5mm, 1.6mm, 1.7mm, 1.8mm, 1.9mm, 2mm, 2.1mm, 2.2mm, 2.3mm, 2.4mm, 2.5mm, 2.6mm, 2.7mm, 2.8mm, 2.9mm, 3.0mm, 3.1mm, 3.2mm, 3.3mm, 3.4mm, 3.5mm, 3.6mm, 3.7mm, 3.8mm, 3.9 ... mm, 3mm, 3.1mm, 3.2mm, 3.3mm, 3.4mm, 3.5mm, 3.6mm, 3.7mm, 3.8mm, 3.9mm, 4mm, 4.1mm, 4.2mm, 4.3mm, 4.4mm, 4.5mm, 4.6mm, 4.7mm, 4.8mm, 4.9mm, 5mm, 5.1mm, 5.2mm, 5.3mm, 5.4mm, 5.5mm, 5.6mm, 5.7mm, 5.8mm, 5.9mm, 6mm etc.
[0064] In an embodiment, an external power source is utilized to reduce the spacing between the nearest conductive materials to, for example, less than 0.01 mm, 0.02 mm, 0.03 mm, 0.04 mm, 0.05 mm, 0.06 mm, 0.07 mm, 0.8 mm, 0.09 mm, 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1 mm, 1.1 mm, 1.2 mm, 1.3 mm, 1.4 mm, 1.5 mm, 1.6 mm, 1.7 mm, 1.8 mm, 1.9 mm, 2 mm, 2.1 mm, 2.2 mm, It can be reduced to 2.3mm, 2.4mm, 2.5mm, 2.6mm, 2.7mm, 2.8mm, 2.9mm, 3mm, 3.1mm, 3.2mm, 3.3mm, 3.4mm, 3.5mm, 3.6mm, 3.7mm, 3.8mm, 3.9mm, 4mm, 4.1mm, 4.2mm, 4.3mm, 4.4mm, 4.5mm, 4.6mm, 4.7mm, 4.8mm, 4.9mm, 5mm, 5.1mm, 5.2mm, 5.3mm, 5.4mm, 5.5mm, 5.6mm, 5.7mm, 5.8mm, 5.9mm, 6mm etc.
[0065] In an embodiment, the density of the conductive material is, for example, 20 per square inch ( / in 2 ), or 30 / in. 2 , or 40 / in. 2 , or 50 / in. 2 , or 60 / in. 2 , or 70 / in. 2 , or 80 / in. 2 , or 90 / in. 2 , or 100 / in 2 , or 150 / in. 2 , or 200 / in. 2 , or 250 / in. 2 , or 300 / in. 2 , or 350 / in. 2 , or 400 / in 2 , or 450 / in. 2 , or 500 / in 2 , or 550 / in. 2 , or 600 / in. 2 , or 650 / in. 2 , or 700 / in2 or 750 / in 2 or may be even larger, etc.
[0066] In one embodiment, the distance between the closest conductive materials is 0.1 mm or less, or 0.2 mm or less, 0.3 mm or less, 0.4 mm or less, 0.5 mm or less, 0.6 mm or less, 0.7 mm or less, 0.8 mm or less, 0.9 mm or less, 1 mm or less, 1.1 mm or less, 1.2 mm or less, 1.3 mm or less, 1.4 mm or less, 1.5 mm or less, 1.6 mm or less, 1.7 mm or less, 1.8 mm or less, 1.9 mm or less, 2 mm or less, 2.1 mm or less, 2.2 mm or less, 2.3 mm or less, 2.4 mm or less, 2.5 mm or less, 2.6 mm or less, 2.7 mm or less, 2.8 mm or less, 2.9 mm or less, 3 mm or less, 3.1 mm or less, 3.2 mm or less, 3.3 mm or less, 3.4 mm or less, 3.5 mm or less, 3.6 mm or less, 3.7 mm or less, 3.8 mm or less, 3.9 mm or less, 4 mm or less, 4.1 mm or less, 4.2 mm or less, 4.3 mm or less, 4.4 mm or less, 4.5 mm or less, 4.6 mm or less, 4.7 mm or less, 4.8 mm or less, 4.9 mm or less, 5 mm or less, 5.1 mm or less, 5.2 mm or less, 5.3 mm or less, 5.4 mm or less, 5.5 mm or less, 5.6 mm or less, 5.7 mm or less, 5.8 mm or less, 5.9 mm or less, 6 mm or less, etc.
[0067] In some embodiments, the spacing between the most adjacent conductive materials is 0.1 mm or more, or 0.2 mm or more, 0.3 mm or more, 0.4 mm or more, 0.5 mm or more, 0.6 mm or more, 0.7 mm or more, 0.8 mm or more, 0.9 mm or more, 1 mm or more, 1.1 mm or more, 1.2 mm or more, 1.3 mm or more, 1.4 mm or more, 1.5 mm or more, 1.6 mm or more, 1.7 mm or more, 1.8 mm or more, 1.9 mm or more, 2 mm or more, 2.1 mm or more, 2.2 mm or more, 2.3 mm or more, 2.4 mm or more, 2.5 mm or more, 2.6 mm or more, 2.7 mm or more, 2.8 mm or more, 2.9 mm or more, 3mm or more, 3.1mm or more, 3.2mm or more, 3.3mm or more, 3.4mm or more, 3.5mm or more, 3.6mm or more, 3.7mm or more, 3.8mm or more, 3.9mm or more, 4mm or more, 4.1mm or more, 4.2mm or more, 4.3mm or more, 4.4mm or more, 4.5mm 4.6 mm or more, 4.7 mm or more, 4.8 mm or more, 4.9 mm or more, 5 mm or more, 5.1 mm or more, 5.2 mm or more, 5.3 mm or more, 5.4 mm or more, 5.5 mm or more, 5.6 mm or more, 5.7 mm or more, 5.8 mm or more, 5.9 mm or more, 6 mm or more, etc.
[0068] In an embodiment, the density of the conductive material is, for example, 20 / in 2 Over or 30 / in 2 Over or 40 / in 2 Over or 50 / in 2 Over or 60 / in 2 Over or 70 / in 2 Over or 80 / in 2 Over or 90 / in 2 Over or 100 / in 2 Over 150 / in 2 Over or 200 / in 2 Over 250 / in 2 Over or 300 / in 2 Over 350 / in 2 Over or 400 / in 2 Over 450 / in 2 Over 500 / in 2 Over 550 / in 2 Over 600 / in2 Over 650 / in 2 Over 700 / in 2 Over 750 / in 2 It could be super, or even larger, etc.
[0069] Disclosed herein is a method for fabricating a surgical instrument comprising: a major surface of a flexible material, the flexible material adapted to be applied to an area of tissue; a first electrode design formed from a first conductive solution comprising a mixture of a polymer and a first element, the first conductive solution being applied in contact with the major surface, the first element comprising a metal species, and the first electrode design comprising at least one dot or reservoir, a selected one of the at least one dot or reservoir having an average diameter of about 1.5 mm + / - 1 mm; and a second electrode design formed from a second conductive solution comprising a mixture of a polymer and a second element, the second element comprising a different metal species than the first element, the second conductive solution being printed in contact with the major surface, and the second electrode design comprising at least one other dot or reservoir and at least one a second electrode design, wherein selected ones of the other dots or reservoirs have an average diameter of about 2.5 mm + / - 2 mm; and a spacing on the major surface between the first and second electrode designs such that the first electrode design is not in physical contact with the second electrode design, the spacing being about 1.5 mm + / - 1 mm, at least the first and second electrode designs being repeated at least once, the at least one repetition of the first electrode design being substantially adjacent to the second electrode design, and the at least one repetition of the first and second electrode designs, in combination with the spacing between the first and second electrode designs, defining at least one pattern of at least one voltaic cell that spontaneously produces at least one electric current when introduced into an electrolyte.Therefore, the electrodes, dots, or reservoirs may be 0.2mm, or 0.3mm, 0.4mm, 0.5mm, 0.6mm, 0.7mm, 0.8mm, 0.9mm, 1.0mm, 1.1mm, 1.2mm, 1.3mm, 1.4mm, 1.5mm, 1.6mm, 1.7mm, 1.8mm, 1.9mm, 2.0mm, 2.1mm, 2.2mm, 2.3mm, 2.4mm, 2.5mm, 2.6mm, 2.7mm, 2.8mm, 2.9mm, 3.0mm, 3.1mm, 3.2mm, 3.3mm, 3.4mm, 3.5mm, 3.6mm, 3.7mm, 3.8mm, 3.9mm, 4.0mm, 4.1mm, 4.2mm, 4.3mm, 4.4mm, 4.5mm, 4.6mm, 4.7mm, 4.8mm, 4.9mm, 5.0mm, 5.1mm, 5.2mm, 5.3mm, 5.4mm, 5.5mm, 5.6mm, 5.7mm, 5.8mm, 5.9mm, 6.0mm, 6.1mm, 6.2mm, 6.3mm, 6.4mm, 6.5mm, 6.6mm, 6.7mm, 6.8mm, 6.9mm, 7.0mm, 7.1mm, 7.2mm, 7.3mm, 7.4mm, 7.5mm, 7.6mm, 7.7mm, 7.8mm, 7.9mm, 8.0mm, 8.1mm, 8.2mm, 8.3mm, 8.4 The average diameter may be 5mm, 2.6mm, 2.7mm, 2.8mm, 2.9mm, 3.0mm, 3.1mm, 3.2mm, 3.3mm, 3.4mm, 3.5mm, 3.6mm, 3.7mm, 3.8mm, 3.9mm, 4.0mm, 4.1mm, 4.2mm, 4.3mm, 4.4mm, 4.5mm, 4.6mm, 4.7mm, 4.8mm, 4.9mm, 5.0mm, etc.
[0070] In further embodiments, the electrodes, dots or reservoirs are 0.2 mm or more, 0.3 mm or more, 0.4 mm or more, 0.5 mm or more, 0.6 mm or more, 0.7 mm or more, 0.8 mm or more, 0.9 mm or more, 1.0 mm or more, 1.1 mm or more, 1.2 mm or more, 1.3 mm or more, 1.4 mm or more, 1.5 mm or more, 1.6 mm or more, 1.7 mm or more, 1.8 mm or more, 1.9 mm or more, 2.0 mm or more, 2.1 mm or more, 2.2 mm or more, 2.3 mm or more, 2.4 mm or more, 2.5 mm or more. or greater, such as 2.6 mm or greater, 2.7 mm or greater, 2.8 mm or greater, 2.9 mm or greater, 3.0 mm or greater, 3.1 mm or greater, 3.2 mm or greater, 3.3 mm or greater, 3.4 mm or greater, 3.5 mm or greater, 3.6 mm or greater, 3.7 mm or greater, 3.8 mm or greater, 3.9 mm or greater, 4.0 mm or greater, 4.1 mm or greater, 4.2 mm or greater, 4.3 mm or greater, 4.4 mm or greater, 4.5 mm or greater, 4.6 mm or greater, 4.7 mm or greater, 4.8 mm or greater, 4.9 mm or greater, 5.0 mm or greater, etc.
[0071] In the actual application form, the electrode and the dot are arranged in a linear manner, 0.2mm or less, 0.3mm or less, 0.4mm or less, 0.5mm or less, 0.6mm or less, 0.7mm or less, 0.8mm or less, 0.9mm or less, 1.0mm or less, 1.1mm or less, 1.2mm or less, 1.3mm or less, 1.4mm or less, 1.5mm or less, 1.6mm or less, 1.7mm or less, 1.8mm or less, 1.9mm or less, 2.0mm or less, 2.1mm or less, 2.2mm or less, 2.3mm or less, 2.4mm or less, 2.5mm or less The average diameters of the diameters are 2.6mm or less, 2.7mm or less, 2.8mm or less, 2.9mm or less, 3.0mm or less, 3.1mm or less, 3.2mm or less, 3.3mm or less, 3.4mm or less, 3.5mm or less, 3.6mm or less, 3.7mm or less, 3.8mm or less, 3.9mm or less, 4.0mm or less, 4.1mm or less, 4.2mm or less, 4.3mm or less, 4.4mm or less, 4.5mm or less, 4.6mm or less, 4.7mm or less, 4.8mm or less, 4.9mm or less, and 5.0mm or less.
[0072] The concentration or amount of material in the first and second reservoirs, and / or the relative size (e.g., size or surface area) of the first and second reservoirs can be purposefully selected to achieve various characteristics of system behavior. For example, the amount of material in the first and second reservoirs can be selected to provide a device that runs at approximately a desired rate and / or has an operating behavior that "dies" after an approximate period of time after activation. In embodiments, the one or more first reservoirs and the one or more second reservoirs are configured to maintain one or more currents for an approximate predetermined time after activation. It should be understood that the amount of time the current is maintained depends on external conditions and factors (e.g., the amount and type of activating agent), and that the current occurs intermittently depending on the presence or absence of the activating agent. Further disclosure regarding the manufacture of reservoirs configured to maintain one or more currents for approximately a predetermined period of time can be found in U.S. Pat. No. 7,904,147, entitled SUBSTANTIALLY PLANAR ARTICLE AND METHODS OF MANUFACTURE, issued March 8, 2011, and is incorporated by reference in its entirety.
[0073] In various embodiments, the difference between the standard potentials of the first and second reservoirs can range from 0.05 V to about 5.0 V. For example, the standard potentials can be 0.05 V, 0.06 V, 0.07 V, 0.08 V, 0.09 V, 0.1 V, 0.2 V, 0.3 V, 0.4 V, 0.5 V, 0.6 V, 0.7 V, 0.8 V, 0.9 V, 1.0 V, 1.1 V, 1.2 V, 1.3 V, 1.4 V, 1.5 V, 1.6 V, 1.7 V, 1.8 V, 1.9 V, 2.0 V, 2.1 V, 2.2 V, 2.3 V, 2.4 V, 2.5 V, 2.6 V, 2.7 V, 2.8 V, 2.9 V, 3.0 V, 3.1 V, 3.2 V, 3.3 V, 3.4 V, 3.5 V, 3.6 V, 3.7 V, 3.8 V, 3.9 ... , 2.3V, 2.4V, 2.5V, 2.6V, 2.7V, 2.8V, 2.9V, 3.0V, 3.1V, 3.2V, 3.3V, 3.4V, 3.5V, 3.6V, 3.7V , 3.8V, 3.9V, 4.0V, 4.1V, 4.2V, 4.3V, 4.4V, 4.5V, 4.6V, 4.7V, 4.8V, 4.9V, 5.0V etc.
[0074] In certain embodiments, the difference between the standard potentials of the first and second reservoirs is at least 0.05 V, at least 0.06 V, at least 0.07 V, at least 0.08 V, at least 0.09 V, at least 0.1 V, at least 0.2 V, at least 0.3 V, at least 0.4 V, at least 0.5 V, at least 0.6 V, at least 0.7 V, at least 0.8 V, at least 0.9 V, at least 1.0 V, at least 1.1 V, at least 1.2 V, at least 1.3 V, at least 1.4 V, at least 1.5 V, at least 1.6 V, at least 1.7 V, at least 1.8 V, at least 1.9 V, at least 2.0 V, at least 2.1 V, at least 2.2 V, at least 2.3 V, at least 2.4 V, at least 2.5 V, at least 2.6 V, at least 2.7 V, at least 2.8 V, at least 2.9 V, at least 3.0 V, at least 3.1 V, at least 3.2 V, at least 3.3 V, at least 3.4 V, at least 3.5 V, at least 3.6 V, at least 3.7 V, at least 3.8 V, at least 3.9 V, at least 4.0 V, at least 4.1 V, at least 4.2 V, at least 4.3 V, at least 4.4 V, at least 4.5 V, at least 4.6 V, at least 4.7 V, at least 4.8 V, at least 4.9 V, at least 5.0 V, at least 5.1 V, at least 5.2 V, at least 5.3 V, at least 5.4 V, at least 5.5 V, at least 5.6 V It can be at least 2.2V, at least 2.3V, at least 2.4V, at least 2.5V, at least 2.6V, at least 2.7V, at least 2.8V, at least 2.9V, at least 3.0V, at least 3.1V, at least 3.2V, at least 3.3V, at least 3.4V, at least 3.5V, at least 3.6V, at least 3.7V, at least 3.8V, at least 3.9V, at least 4.0V, at least 4.1V, at least 4.2V, at least 4.3V, at least 4.4V, at least 4.5V, at least 4.6V, at least 4.7V, at least 4.8V, at least 4.9V, at least 5.0V, etc.
[0075] In certain embodiments, the difference between the standard potentials of the first and second reservoirs is 0.05V or less, 0.06V or less, 0.07V or less, 0.08V or less, 0.09V or less, 0.1V or less, 0.2V or less, 0.3V or less, 0.4V or less, 0.5V or less, 0.6V or less, 0.7V or less, 0.8V or less, 0.9V or less, 1.0V or less, 1.1V or less, 1.2V or less, 1.3V or less, 1.4V or less, 1.5V or less, 1.6V or less, 1.7V or less, 1.8V or less, 1.9V or less, 2.0V or less, 2.1V or less. The potential difference may be 2.2V or less, 2.3V or less, 2.4V or less, 2.5V or less, 2.6V or less, 2.7V or less, 2.8V or less, 2.9V or less, 3.0V or less, 3.1V or less, 3.2V or less, 3.3V or less, 3.4V or less, 3.5V or less, 3.6V or less, 3.7V or less, 3.8V or less, 3.9V or less, 4.0V or less, 4.1V or less, 4.2V or less, 4.3V or less, 4.4V or less, 4.5V or less, 4.6V or less, 4.7V or less, 4.8V or less, 4.9V or less, 5.0V or less, etc. In embodiments having very small reservoirs (e.g., nanometer scale), the difference in standard potentials may be substantially less or more. Electrons passing between the first reservoir and the second reservoir may be generated as a result of the difference in standard potentials. Further disclosure regarding standard potentials can be found in U.S. Pat. No. 8,224,439, entitled BATTERIES AND METHODS OF MANUFACTURE AND USE, issued Jul. 17, 2012, and incorporated herein by reference in its entirety.
[0076] The voltage present at the treatment site is typically in the millivolt range, but the disclosed embodiments can introduce much higher voltages, for example, approaching 1 volt, when using the dissimilar metals previously described with 1 mm spacing. Additionally, in embodiments utilizing AC power, the voltage can vary or be periodic over time. In embodiments, the higher voltage can drive the current deeper into the treatment area so that the dermis and neodermis benefit from the simulated current of the wound. In this way, the current can not only drive the silver and zinc into the treatment area, but also provide a stimulating current so that the entire surface area heals simultaneously. In embodiments, the current can, for example, kill microorganisms. In embodiments, the electric field can, for example, kill microorganisms.
[0077] Embodiments of the present disclosure relating to the treatment of a disease or condition or symptom may also include selection of a patient or tissue in need of, or that would benefit from, treatment of the disease or condition or symptom.
[0078] While various embodiments have been illustrated and described, it will be understood that changes and modifications can be made without departing from the scope of the appended claims.
[0079] Certain embodiments disclosed herein include a method of making a substantially planar LLMC or LLEF system, the method comprising: bonding a plurality of first reservoirs to a substrate, selected ones of the plurality of first reservoirs comprising a reducing agent and a first reservoir surface of the selected ones of the plurality of first reservoirs being adjacent to a first substrate surface; and bonding a plurality of second reservoirs to the substrate, selected ones of the plurality of second reservoirs comprising an oxidizing agent and a second reservoir surface of the selected ones of the plurality of second reservoirs being adjacent to the first substrate surface; wherein bonding the plurality of first reservoirs and bonding the plurality of second reservoirs comprises bonding using tattoos. In embodiments, the substrate may comprise gauze comprising dots or electrodes.
[0080] Further embodiments may include a method of making a LLMC or LLEF system, the method comprising: coupling a plurality of first reservoirs with a substrate, selected ones of the plurality of first reservoirs comprising a reducing agent, and a first reservoir surface of the selected ones of the plurality of first reservoirs being proximate to a first substrate surface; and coupling a plurality of second reservoirs with a substrate, selected ones of the plurality of second reservoirs comprising an oxidizing agent, and a second reservoir surface of the selected ones of the plurality of second reservoirs being proximate to the first substrate surface; the bonding of the plurality of first reservoirs and the bonding of the plurality of second reservoirs includes combining the plurality of first reservoirs, the plurality of second reservoirs and the plurality of parallel insulators to produce a pattern repetition arranged in a first direction across the plane, the pattern repetition including an arrangement of a first one of the parallel insulators and one of the plurality of first reservoirs and a second one of the parallel insulators and one of the plurality of second reservoirs; and weaving a plurality of transverse insulators in a second direction across the plane through the first parallel insulators, the one first reservoir, the second parallel insulator and the one second reservoir to form a woven device.
[0081] Further disclosed embodiments include a system comprising a "clip" as described herein and a dressing or substrate comprising a multi-array matrix of biocompatible microcells. In embodiments, said clip comprises a device that includes a "slit" extending from the center of the device to the periphery of the device to allow attachment of the device to a fixation connector rod (as seen in FIG. 21).
[0082] Disclosed embodiments of the clip include "hole" shapes or voids in the slits, as shown in FIG. 18. In embodiments, the holes are, for example, 2 mm in diameter, 3 mm in diameter, 4 mm in diameter, 5 mm in diameter, 6 mm in diameter, 7 mm in diameter, 8 mm in diameter, or even larger. In further embodiments, the holes are, for example, at least 2 mm in diameter, at least 3 mm in diameter, at least 4 mm in diameter, at least 5 mm in diameter, at least 6 mm in diameter, at least 7 mm in diameter, at least 8 mm in diameter, or even larger. In embodiments, the device includes multiple holes along the slits. In embodiments, the hole closest to the center of the device is the smallest of the multiple holes, and gets larger as you approach the periphery (as shown in FIG. 18, 220 in FIG. 22).
[0083] LLMC / LLEF System - How to Use
[0084] Treatment of external fixation device insertion site
[0085] Disclosed embodiments include methods for preventing or limiting infection at the insertion site of an external fixation device. For example, the disclosed methods may include applying a bioelectric medical device, e.g., a dressing and fixation device, to a patient undergoing treatment with an external fixation device. The fixation device may include a "pin-clip" fixation device. The clip may include a "slit" or "groove" with a circular area that can accommodate the pass-through of the external fixation device. In embodiments, the slit or groove may extend from the periphery of the device toward the center of the device.
[0086] The disclosed embodiments include, for example: A. Stabilization of severe open fractures b. Stabilization of an infected nonunion c. Correction of limb misalignment and length discrepancy d. Initial stabilization of soft tissue and bone fractures in polytrauma patients (Damage Control Orthopedics) e. Closed fracture associated with severe soft tissue injury f. Severe comminution lesions at the epiphysis and around the joints g. Temporary transarticular stabilization of severe soft tissue and ligament injuries h. Pelvic train disorder i. Specific pediatric fractures j. Arthrodesis K. Ligamentotaxis l. Bone cutting m. Open fractures with significant destruction of soft tissues (e.g., type II or type III open fractures) n. Soft tissue injury (burns, etc.) o. Acetabular and pelvic fractures p. Severely comminuted and unstable fractures q. Fractures associated with bone defects r. Limb lengthening S. Fractures associated with infection or nonunion and related external fixation treatments.
[0087] In an embodiment, a method for treating or dressing an external fixation insertion site includes administering an additional material locally onto the surface of the wound or onto the biocompatible microcellular matrix. Such additional material may comprise, for example, activating gel, rhPDGF (REGRANEX®), vibronectin:IGF complex, CELLSPRAY®, RECELL®, INTEGRA® Dermal Regeneration Template, BIOMEND®, INFUSE®, ALLODERM®, CYMETRA®, SEPRAPACK®, SEPRAMESH®, SKITEMP®, MEDFIL®, COSMODERM®, COSMOPLAST®, OP-1®, ISOLAGEN®, CARTICEL®, APLIGRAF®, DERMAGRAFT®, TRANSCYTE®, ORCEL®, EPICEL®, and the like. In embodiments, the activating gel may be, for example, TEGADERM® 91110 by 3M, MEPILEX Normal Gel 0.9% Sodium Chloride, HISPAGEL®, LUBRIGEL®, or other compositions useful for maintaining a moist environment around the wound or useful for healing the wound via another mechanism.
[0088] Aspects herein provide, in part, a method of reducing symptoms associated with an insertion site, in aspects of this embodiment, the symptoms reduced are infection, swelling, congestion, erythema, bruising, tenderness, stiffness, swelling, fever, chills, breathing problems, fluid retention, blood clotting, loss of appetite, increased heart rate, granulomas, fibrosis, pus, or non-viscous serous fluid, ulcer formation, or pain.
[0089] Biofilm Treatment
[0090] The disclosed embodiments of the LLMC and LLEF systems can provide antimicrobial effects. For example, the disclosed embodiments can prevent, limit, or reduce biofilm formation by intervening in bacterial signaling. For example, the disclosed methods and devices can prevent biofilm formation at the insertion site of an external fixation device.
[0091] Further embodiments can kill bacteria through an established biofilm.
[0092] (Example) The following non-limiting examples are provided for illustrative purposes only to facilitate a more complete understanding of representative embodiments, and should not be construed as limiting any of the embodiments described herein, including those related to methods of healing wounds.
[0093] Example 1 (Regulation of bacterial gene expression and enzyme activity) Treatment of biofilms is a major challenge, as bacteria present in biofilms have a strong defense against the host immune response and are significantly more resistant to antibiotics. Bacteria present in biofilms are encapsulated in an extracellular matrix consisting of several components, including polysaccharides and DNA, which acts as a nucleic acid barrier between the embedded bacteria and the surrounding environment and impedes the penetration of antimicrobial agents. Furthermore, due to limited access to nutrients, bacteria present in biofilms have a low metabolic and dormant physiological state, which increases their resistance to antibiotics.
[0094] Chronic wounds are a socio-economic problem, with an estimated 1-2% of the Western population suffering from chronic ulcers, and roughly 2-4% of national medical budgets in developed countries being spent on chronic wound treatment and complications. The incidence of non-healing wounds is thought to rise as a natural consequence of longer life spans and lifestyle changes such as obesity, diabetes, and cardiovascular disease. Non-healing skin marine is prone to infection with biofilms. Multiple bacterial species are present in chronic wounds, with Pseudomonas aeruginos being the most common, especially in larger wounds. Pseudomonas aeruginos has been suspected to delay the healing of leg ulcers. It has also been estimated that the surgical success rate of split-thickness skin grafts and the overall healing rate of chronic venous ulcers are reduced in the presence of clinical infection with Pseudomonas aeruginosa.
[0095] Pseudomonas aeruginosa biofilms may be associated with chronic wound infections. The BED (disclosed herein as "BED" or "Bioelectric Device" or "PROCELLERA®") is composed of a matrix of silver-zinc bonded biocompatible microcells that activates in the presence of conductive wound exudate, generating an electric field (0.3-0.9 V). Growth (measured as OD and cfu) of pathogenic Pseudomonas aeruginosa strain PAO1 in LB medium was significantly inhibited in the presence of BED. PAO1 biofilms were created using an in vitro polycarbonate filter model. Bacteria grown overnight at 37°C in LB medium were plated onto sterile polycarbonate membrane filters placed on LB agar plates to allow 48 hours for the formation of developed biofilms. Biofilms were then exposed to BED or placebo for 24 hours. Structural analysis using scanning electron microscopy showed that BED significantly disrupted biofilm integrity, compared with no significant effect seen with a commercial silver dressing commonly used in wound treatment. Staining for extracellular polymeric substances, PAO1 staining, and vital staining were performed. Color indicated that biofilm thickness and viable bacterial cell counts were reduced in the presence of BED (n=4). BED suppressed the expression of quorum sensing genes lasR and rhlR (p<0.05, n=3). BED was also found to generate micromolar amounts of superoxide, a known reducing agent that suppresses genes of the redox-sensing multidrug efflux systems mexAB and mexEF (n=3, p<0.05). BED also downregulated glycerol-3-phosphate dehydrogenase, an electric field-sensitive enzyme involved in bacterial respiration, glycolysis, and phospholipid biosynthesis (p<0.05, n=3).
[0096] Materials and Methods
[0097] (In vitro biofilm model)
[0098] PAO1 biofilms were generated using an in vitro polycarbonate filter model. Cells were grown overnight at 37°C in LB medium, and bacteria were plated onto sterile polycarbonate membrane filters placed on LB agar plates to allow for 48 hours for the formation of developed biofilms. Biofilms were then exposed to BED or placebo for 24 hours.
[0099] (Energy Dispersive X-ray Spectroscopy (EDS))
[0100] EDS elemental analysis of the Ag / ZN BED was carried out in an environmental scanning electron microscope (ESEM, FEI XL-30) at 25 kV. A thin layer of carbon was deposited on the surface of the dressing to increase electrical conductivity.
[0101] (Scanning Electron Microscope)
[0102] Biofilms were grown on circular membranes and then fixed in 4% formaldehyde / 2% glutaraldehyde for 48 h at 4°C, washed in phosphate buffered saline, dehydrated in a graded ethanol series, critical point dried, and mounted on aluminum stubs. Samples were then sputter coated with platinum (Pt) and imaged by SEM (XL30S; FEG, FEI, Hillsboro, OR) at 5 kV in secondary electron mode.
[0103] (Live / Dead dyeing)
[0104] The viability of the bacterial population was monitored using the LIVE / DEAD BacLight Bacterial Viability Kit for microscopy and quantitative assays: cells that are considered dead or dead with compromised membranes stain red, whereas cells with intact membranes stain green.
[0105] (EPR spectroscopy)
[0106] EPR measurements were performed at room temperature using a Bruker ER 300 EPR spectrometer with a TM110 cavity operating at X-band. The microwave frequency was measured with an EIP575 source-locked microwave counter (EIP Microwave, San Jose, CA). The instrument settings used in the spin-trapping studies were as follows: modulation amplitude 0.32 G, time constant 0.16 s, scan time 60 s, modulation frequency 100 kHz, microwave power 20 mW, microwave frequency 9.76 GHz. The samples were placed in a quartz EPR flat cell and the spectra were recorded at ambient temperature (25 °C). EPR measurements were performed continuously for 1 min. Spectral components were identified, simulated, and quantified as reported. The double integrals of the DEPMPO experimental spectra were compared to those of a 1 mM TEMPO sample measured with the same settings to estimate the concentration of the superoxide adducts.
[0107] Quantification of mRNA and miRNA expression
[0108] Total RNA, including miRNA, was isolated using the Norgen RNA isolation kit according to the manufacturer's protocol. Gene expression levels were quantified by real-time PCR system and SYBR Green (Applied Biosystems) and normalized with nadB and ProC as housekeeping genes. Expression levels were quantified using the 2(-ΔΔct) comparative quantification method.
[0109] (Glycerol-3-phosphate dehydrogenase assay)
[0110] Glycerol-3-phosphate dehydrogenase assays were performed using an assay kit from Biovision according to the manufacturer's instructions. Briefly, cells (~1 × 10 6 ) was homogenized on ice for 10 minutes with 200 μL of ice-cold GPDH assay buffer, and the OD was measured using the supernatant, and the GPDH activity was calculated from the results.
[0111] statistics
[0112] Control and treated samples were compared by paired t-test. Student's t-test was used for comparisons between other means. P<0.05 was considered significant.
[0113] (Ag / Zn BED destroys Pseudomonas aeruginosa biofilms)
[0114] To confirm the chemical composition of the dressing, we collected high-resolution electron micrographs using an environmental scanning electron microscope. Our elemental mapping shows that the silver particles are concentrated in the gold dots and the zinc particles in the grey dots on the polyester fabric.
[0115] As shown in Figure 9A, P. aeruginosa was grown in LB medium in round-bottom tubes with continuous shaking and absorbance was measured by calculating the optical density at 600 nm at each time point. Ag / Zn BED and control dressing with equivalent amount of silver were confirmed to inhibit bacterial growth (n=4) (Figure 9B, C). When bacteria were cultured on agar medium with Ag / Zn BED dressing or on agar medium embedded with placebo, the Ag / Zn BED showed a clear inhibition zone, indicating bacteriostatic, while the placebo with silver dressing showed a smaller inhibition zone, indicating an effective role of electric field compared to local contact (Figure 9D). However, as evident from scanning electron microscopy images (Figure 10), EPS staining (Figure 11), and live / dead staining (Figure 12), Ag / Zn BED destroys biofilms well, while silver has no effect on biofilm destruction. Silver has been recognized for its antimicrobial properties for centuries. Most of the studies on the antibacterial effects of silver, especially those focused on wound healing, have been carried out on planktonic bacteria. Silver ions bind and react with proteins and enzymes, thereby causing structural changes in bacterial cell walls and membranes, inducing cell disintegration and bacterial death. Silver also binds to DNA and RNA, thereby disrupting basic biological processes.
[0116] Silver is an effective agent against mature biofilms of P. aeruginosa, but only at high concentrations. It has been reported that silver sulfadiazine at concentrations of 5-10 μg / mL eradicates biofilms, but is ineffective at lower concentrations (1 μg / mL). Thus, the silver concentrations in currently available wound dressings are too low for the treatment of chronic biofilm wounds. Figure 13 shows PAO1 staining of biofilms showing that the mushroom-like higher-order structures are absent in Ag / Zn BED-treated samples.
[0117] (Ag / Zn BED downregulates quorum sensing genes)
[0118] The pathogenicity of P. aeruginosa can be attributed to various virulence factors. Many of these extracellular virulence factors are produced only when the bacterial cell density reaches a threshold (quorum). Quorum sensing is primarily regulated by two cell-cell signaling systems, called las and rhl, which are both composed of transcriptional regulators (LasR and RhlR, respectively) and autoinducer synthesis enzymes (LasI and RhlI, respectively). In P. aeruginosa, LasI produces 3OC12-HSL. LasR then responds to this signal, and the LasR:3OC12-HSL complex activates many genes, including rhlR, which encodes a quorum-sensing receptor [26-30], which binds to the autoinducer C4-HSL produced by RhlI. RhlR:C4-HSL also mediates large-scale gene regulation. P. aeruginosa lacking QS is impaired in its ability to form biofilms. Quorum sensing inhibitors increase the susceptibility of biofilms to multiple classes of antibiotics.
[0119] To test the effect of electric field on quorum sensing genes, we subjected mature biofilms to Ag / Zen BED or placebo for 12 hours and observed gene expression levels. In previous experiments, most bacteria under Ag / Zen BED treatment were killed by 24 hours, so we chose the earlier time point. We found significant downregulation of lasR and rhlR (n=4, p<0.05). It has been reported that the transcription of lasR is weakly correlated with the transcription of lasA, lasB, toxA and aprA. However, we found that it downregulated them in Ag / Zen BED-treated samples at the 24 hour time point (data not shown), but no significant difference was found in their expression levels at this time point (Figure 14).
[0120] Ag / Zen BED inhibits redox-sensing multidrug efflux system in Pseudomonas aeruginosa.
[0121] Ag / Zen BED functions as a reducing agent and reduces protein thiols. Superoxide anion is generated by one-electron reduction of oxygen molecule O2. Molecular oxygen (oxygen molecule) contains two unpaired electrons. The addition of the second electron fills one of the degenerate molecular orbitals, generating a charged ionic species with one unpaired electron that exhibits paramagnetism. Superoxide anion, which can function as a biological reducing agent and reduce disulfide bonds, is eventually converted to hydrogen peroxide, which is known to have antibacterial properties. In this paper, we use electron paramagnetic resonance (EPR) to directly detect superoxide exposed to bioelectrical dressing. Superoxide spin trapping was performed using DEPMPO (2-(diethoxyphosphoryl)-2-methyl-3,4-dihydro-2H-pyrrole 1-oxide), and ~1 μM superoxide anion was detected by exposure to Ag / Zen BED for 40 min (Figure 15). MexR and MexT are multidrug efflux regulators of P. aeruginosa that utilize an oxidation-sensing mechanism. Oxidation of both MexR and MexT activates them by forming intramolecular disulfide bonds, leading to their detachment from the promoter DNA and derepressing MexAB-oprM and MexEF-oprN, respectively, but the operons cannot be transcribed under reduced conditions. Induction of the Mex operon leads to increased antibacterial resistance as well as suppression of the quorum-sensing cascade and several virulence factors. In Ag / Zen BED-treated samples, MexR and MexT were in the reduced and inactive forms, and downregulation of the downstream Mex genes MexA, MexB, MexE, and MexF (but not MexC and MexD) was observed (n=4, p<0.05). To confirm the reducing activity of Ag / Zen BED, the experiment was repeated using 10 mM DTT, and similar results were obtained (Figure 16).
[0122] (Ag / Zen BED reduces glycerol-3-phosphate dehydrogenase enzyme activity)
[0123] Electric fields can affect the molecular charge distribution in many enzymes. Glycerol-3-phosphate dehydrogenase is an enzyme involved in respiration, glycolysis, and phospholipid biosynthesis and is thought to be affected by external electric fields in P. aeruginosa. Treatment of P. aeruginosa biofilms with Ag / Zen BED for 12 hours resulted in a significant decrease in glycerol-3-phosphate dehydrogenase enzyme activity (n=3).
[0124] Example 2 (Effect of LLMC on biofilm properties) In this study, ten clinical wound pathogens associated with chronic wound infections were used to evaluate the antibiofilm properties of LLMC. For evaluation of the efficacy of wound dressings in biofilm inhibition, hydrogel and drip flow reactor (DFR) biofilm models were used. Biofilms formed with clinical isolates of Acinetobacter baumannii, Corynebacterium amycolatum, Escherichia coli, Enterobacter aerogenes, Enterococcus faecalis CI 4413, Klebsiella pneumonia, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, and Streptococcus equi were evaluated. Antimicrobial susceptibility testing of the biofilms demonstrated that both biofilm models inhibited the biofilm activity of ten clinical isolates. 5CFU / mL of bacteria were used. In the poloxamer hydrogel model, LLMC (25 mm diameter) was directly applied to bacterial biofilms formed on 30% poloxamer hydrogel and on Muller-Hinton agar medium and incubated at 37°C for 24 h to observe growth inhibition. In the DFR biofilm model, bacteria were attached on a polycarbonate membrane as an abiotic surface, and a sample dressing was applied on the membrane. DFR biofilms were incubated in diluted trypticase soy broth (TSB) at room temperature for 72 h. Biofilm formation was evaluated by crystal violet staining under an optical microscope, and antibiofilm effects were evaluated by the reduction in bacterial numbers.
[0125] Example 3 (Regulation of mammalian gene expression and enzyme activity) Primary human skin fibroblasts were grown overnight at 37°C in LB medium and then plated on sterile polycarbonate membrane filters placed on LB agar plates for 48 hours. The cells were then exposed to BED or a placebo for 24 hours. BED suppressed the expression of glycerol-3-phosphate dehydrogenase. BED also downregulated the activity of glycerol-3-phosphate dehydrogenase.
[0126] Example 4 (Regulation of insect gene expression and enzyme activity) Drosophila S2 cells grown overnight at 37°C in LB medium were plated on sterile polycarbonate membrane filters placed on LB agar plates for 48 hours. The cells were then exposed to BED or a placebo for 24 hours. BED inhibits the expression of insect P450 enzymes. BED down-regulated the activity of insect P450 enzymes.
[0127] Example 5 (Treatment for leg fractures) A 40 year old male suffered a shattered lower leg in a motorcycle accident. The fracture was stabilized with an external fixation device. The rod that attaches the device to the bone enters the body via a dressing that contains an array of biocompatible electrodes as described above. The dressing is secured to the rod at the body insertion point using clips as described herein and seen in Figures 18-20.
[0128] Example 6 (Treatment for leg fractures) A 40 year old woman shattered her upper leg in a boating accident. The fracture was stabilized with an external fixation device. The rod that attaches the device to the bone enters the body via a dressing that contains an array of biocompatible electrodes as described above. The dressing is secured to the rod at the body entry point with clips as described herein and seen in Figures 18-20.
[0129] Example 7 (Treatment for ankle fractures) A 20 year old female shattered her ankle in a soccer accident. The fracture was fixed with an external fixation device. The rod that attaches the device to the bone enters the body via a dressing that contains an array of biocompatible electrodes as described above. The dressing is secured to the rod at the body insertion point with clips such as those described herein and seen in Figures 18-20.
[0130] Finally, although aspects of the present specification are emphasized by reference to specific embodiments, it should be understood that those skilled in the art will readily appreciate that these disclosed embodiments merely illustrate the principles of the subject matter disclosed herein. Thus, it should be understood that the disclosed subject matter is not limited to the specific methodology, protocols and / or reagents, etc., described herein. Thus, various modifications or variations of the disclosed subject matter or alternative configurations can be made in accordance with the teachings of the present specification without departing from the spirit of the present specification. Finally, the terms used in the present specification are for the purpose of describing only specific embodiments and are not intended to limit the scope of the present disclosure, which is defined solely by the claims. Thus, the embodiments of the present disclosure are not limited to those precisely as shown and described.
[0131] Certain embodiments are described herein, including the best mode known to the inventors for carrying out the methods and apparatus described herein. Of course, variations on these described embodiments will become apparent to those skilled in the art upon reading the foregoing description. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the appended claims as permitted by applicable law. Moreover, any combination of the above-described embodiments in all possible variations is encompassed by this disclosure unless otherwise expressly stated herein or otherwise clearly contradicted by context.
[0132] Groupings of alternative embodiments, elements, or steps in the present disclosure should not be construed as limitations. Each group member may be referenced and claimed individually or in any combination with other group members disclosed herein. It is anticipated that for reasons of convenience or patentability, one or more members of a group may be included in, or deleted from, a group. When such inclusion or deletion occurs, the specification is deemed to include the modified group and satisfies all recitations of the Markush group as used in the appended claims.
[0133] Unless otherwise indicated, all numerical values expressing features, items, quantities, parameters, characteristics, terms, etc. used in the specification and claims should be understood to be modified in all instances by the term "about". As used herein, the term "about" means that the feature, item, quantity, parameter, characteristic, or term so modified encompasses a range of +10 percent above or -10 percent below the feature, item, quantity, parameter, characteristic, or term. Thus, unless indicated to the contrary, the numerical parameters set forth in this specification and the appended claims are approximations that may vary. At the very least, no attempt is made to limit the scope of the claims to equivalents, and each numerical indication should at least be construed in light of the number of significant digits reported and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and values setting forth the broad scope of the present disclosure are approximations, the numerical ranges and values set forth in the specific examples are reported as precisely as possible. However, any numerical range or value inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. The recitation of numerical ranges herein is merely intended as a shorthand method of referring individually to each individual value falling within the range, and unless expressly stated otherwise herein, each individual value of the numerical range is incorporated herein as if each individual value were individually set forth herein.
[0134] The terms "a," "an," "the," and similar references used in the context of describing this disclosure (particularly in the context of the claims below) should be construed to cover both the singular and the plural, unless otherwise stated or clearly contradicted by context. All methods described herein can be performed in any suitable order, unless otherwise stated herein or clearly contradicted by context. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended to better illuminate the disclosure and does not limit the scope of the invention as otherwise claimed. Nothing in this specification should be construed as indicating any non-claimed element essential to the practice of the embodiments described herein.
[0135] Some of the embodiments disclosed herein may be further limited in the claims by the use of the phrases "consisting of" or "consisting essentially of." When used in a claim, whether as filed or added by amendment, the transitional phrase "consisting of" excludes any element, step, or ingredient not specified in the claim. The transitional phrase "consisting essentially of" limits the scope of the claim to the particular materials or steps, and those that do not materially affect the basic and novel characteristic(s). The embodiments of the present disclosure so claimed are essentially or explicitly described and enabled herein.
[0136] (Additional Note) (Appendix 1) Clips, and a bioelectric device including one or more biocompatible electrodes configured to generate at least one of a low level electric field (LLEF) or a low level microcurrent (LLMC); Including, A system for treating a body entry point for a medical treatment device.
[0137] (Appendix 2) the biocompatible electrode comprises a first array including a pattern of microcells formed from a first conductive material and a second array including a pattern of microcells formed from a second conductive material; 2. The bioelectrical device of claim 1.
[0138] (Appendix 3) the first conductive material and the second conductive material are the same material; 3. The bioelectrical device of claim 2.
[0139] (Appendix 4) the first and second arrays each comprising discrete circuitry; 4. The bioelectrical device of claim 3.
[0140] (Appendix 5) Further comprising a power source. 5. The bioelectrical device of claim 4.
[0141] (Appendix 6) The first array and the second array spontaneously generate LLEFs. 3. The bioelectrical device of claim 2.
[0142] (Appendix 7) the first array and the second array spontaneously generate LLMCs when contacted with an electrolyte; 7. The bioelectric device of claim 6.
[0143] (Appendix 8) a substrate including one or more biocompatible electrodes configured to generate at least one of a low level electric field (LLEF) or a low level microcurrent (LLMC); A bioelectrical device for treating the insertion points of external fixation devices.
[0144] (Appendix 9) the biocompatible electrode comprises a first array including a pattern of microcells formed from a first conductive material and a second array including a pattern of microcells formed from a second conductive material; 9. The bioelectric device of claim 8.
[0145] (Appendix 10) the first conductive material and the second conductive material are the same material; 10. The bioelectric device of claim 9.
[0146] (Appendix 11) the first and second arrays each comprising discrete circuitry; 11. The bioelectric device of claim 10.
[0147] (Appendix 12) Further comprising a power source. 12. The bioelectric device of claim 11.
[0148] (Appendix 13) The first array and the second array spontaneously generate LLEFs. 10. The bioelectric device of claim 9.
[0149] (Appendix 14) the first array and the second array spontaneously generate LLMCs when contacted with an electrolyte; 14. The bioelectrical device of claim 13.
[0150] (Appendix 15) 1. A method for treating a body entry point of an external fixation device, comprising: applying to the body insertion point a system including a clip and a bioelectric device including one or more biocompatible electrodes configured to generate at least one of a low level electric field (LLEF) or a low level microcurrent (LLMC); method.
[0151] (Appendix 16) The applying includes attaching the LLMC system to a flexible substrate having a multi-array matrix of biocompatible microcells on the surface thereof. 16. The method according to claim 15.
[0152] (Appendix 17) The multi-array matrix comprises: a first array including a pattern of microcells including a conductive material; and a second array including a pattern of microcells including a conductive material; Equipped with Both such arrays may define at least one voltaic cell for spontaneously generating at least one electric current together with the conductive material of the first array when the first and second arrays are introduced into an electrolyte. 17. The method according to claim 16.
Claims
1. A clip having a circular area capable of receiving an external fixation device; a bioelectric device including one or more biocompatible electrodes configured to generate at least one of a low level electric field (LLEF) or a low level microcurrent (LLMC); Including, A system for treating areas where an external fixation device enters the body.
2. The biocompatible electrode comprises a first array including a pattern of microcells formed from a first conductive material and a second array including a pattern of microcells formed from a second conductive material. The system of claim 1 .
3. the first conductive material and the second conductive material are the same material; The system of claim 2.
4. the first array and the second array each comprise discrete circuitry; The system of claim 3.
5. Further comprising a power source. The system of claim 4.
6. The first array and the second array spontaneously generate LLEFs. The system of claim 2.
7. the first array and the second array spontaneously generate LLMCs when contacted with an electrolyte; The system of claim 6.
8. A bioelectrical device for treating a site where an external fixation device enters the body, comprising: The bioelectric device includes a substrate including one or more biocompatible electrodes configured to generate at least one of a low level electric field (LLEF) or a low level microcurrent (LLMC); the substrate includes a slit extending from a center of the bioelectric device to a periphery of the bioelectric device; Bioelectrical device.
9. The biocompatible electrode comprises a first array including a pattern of microcells formed from a first conductive material and a second array including a pattern of microcells formed from a second conductive material.
9. The bioelectrical device of claim 8.
10. the first conductive material and the second conductive material are the same material; 10. The bioelectrical device of claim 9.
11. the first array and the second array each comprise discrete circuitry; 11. The bioelectrical device of claim 10.
12. Further comprising a power source.
12. The bioelectrical device of claim 11.
13. The first array and the second array spontaneously generate LLEFs.
10. The bioelectrical device of claim 9.
14. the first array and the second array spontaneously generate LLMCs when contacted with an electrolyte; 14. The bioelectrical device of claim 13.
Citation Information
Patent Citations
medical dressing
JP1997508045A
Medical device and method of manufacturing medical device
JP2008513172A
Electric stimulation treatment tool
JP2016055178A
Method and device for wound treatment
JP2016516549A
Pin site wound protection system
US20090149891A1
